Using a reminder app to improve skin care for breast cancer patients during radiation therapy
Official title: Dermatitis During Adjuvant Irradiation for BREAst Cancer: Grade ≥2 Radiation Dermatitis in Breast Cancer Patients with or Without a Mobile Application (Reminder-App)
Run by University Hospital Schleswig-Holstein · NCT06483477 · Data updated 2026-11-12
This study tests if a reminder app can help breast cancer patients take better care of their skin during radiation therapy and reduce skin problems.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 268 (estimated) |
| Sponsor | University Hospital Schleswig-Holstein Academic / other |
| Drugs / interventions | radiation |
| Locations | 5 sites (Vejle, Southern Denmark and 4 other locations) |
| Status | Recruiting |
| Started | December 23, 2024 |
| Main results expected | September 30, 2026 |
| Study ends | September 30, 2026 |
| Registry record updated | January 16, 2025 |
| Trial ID | NCT06483477 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are female patients aged 18 and older with histologically proven invasive breast cancer who are scheduled for adjuvant radiotherapy and can use a smartphone.
✕Probably not a fit
Patients who are pregnant, lactating, or expected to be non-compliant with the treatment protocol may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This trial evaluates the effectiveness of a reminder app designed to prompt breast cancer patients to perform necessary skin care routines during adjuvant radiotherapy. A total of 268 patients will be randomly assigned to either receive standard skin care with the app or standard skin care alone. The primary goal is to determine if the app can reduce the incidence of grade ≥2 radiation dermatitis. Secondary objectives include assessing pain levels, patient satisfaction with the app, and the app's impact on health technology usage.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the severity of radiation dermatitis in breast cancer patients undergoing treatment.
How similar studies have gone: While the use of mobile applications in healthcare is growing, this specific approach to managing radiation dermatitis is relatively novel and has not been extensively tested in previous studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Histologically proven invasive breast cancer 2. Indication for adjuvant hypo-fractionated radiotherapy 3. Possession of and ability to use a smartphone 4. Female gender 5. Age ≥18 years 6. Written informed consent 7. Capacity of the patient to contract Exclusion Criteria: 1. Pregnancy, Lactation 2. Expected non-compliance
Where it's running
-
Department of Radiation Oncology, University of Lübeck and University Medical Center Schleswig-Holstein
Lübeck, Germany Recruiting -
Vejle Hospital, University Hospital of Southern Denmark
Vejle, Southern Denmark, Denmark Not yet recruiting -
Medical Practice for Radiotherapy and Radiation Oncology
Hanover, Lower Saxony, Germany Not yet recruiting -
Medical School Hamburg, Schwerin Campus
Schwerin, Mecklenburg-Vorpommern, Germany Not yet recruiting -
Malteser Hospital St. Franziskus
Flensburg, Schleswig-Holstein, Germany Not yet recruiting
Study contacts
- Principal investigator: Dirk Rades, MD, FASTRO — Dept. of Radiation Oncology, University of Lubeck, Germany
- Study coordinator: Dirk Rades, MD, FASTRO
- Email: DIRK.RADES@UKSH.DE
- Phone: 0049-451-500
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Oncoliq blood test for early detection of breast cancer
This project will test whether a blood-based miRNA panel (the Oncoliq Test) can detect early breast cancer in adults 40–70 by comparing newly diagnosed, untreated patients with cancer-free controls.
-
Different skin care approaches to prevent skin reactions after mastectomy radiation
This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.
-
Negative pressure wound therapy after mastectomy
This study tests whether a negative pressure dressing after mastectomy reduces fluid build‑up and common wound complications in women with breast cancer.
-
ATUSA 3D automated breast ultrasound for suspicious breast lesions
This study will test whether the ATUSA 3D automated breast ultrasound system can produce high-quality images that match biopsy results in women with BI-RADS 4 or 5 breast findings.
-
Support tool for women with HR+ breast cancer on long-term endocrine therapy
This study tests a SHIELD web- and app-based portal to help women with hormone receptor–positive breast cancer manage symptoms while on long-term endocrine treatment.
-
Conformal ablative radiotherapy for older women with localized ER-positive, HER2-negative breast cancer choosing non-surgical care
This study will test whether five focused SABR treatments can control ER-positive, HER2-negative breast tumors up to 5 cm in women aged 65 and older who are opting for non-surgical management.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.